A Prospective Study of Cancer-Related Fatigue in Women Undergoing Radiotherapy for Breast Cancer
M. Torres,T. Liu,H. Chen,K. Godette,L. Stapleford,D. Mister,M. Castro,J. Li,T. W. Pace,A. H. Miller
DOI: https://doi.org/10.1016/j.ijrobp.2011.06.132
2011-01-01
Abstract:Cancer-related fatigue is a distressing, persistent sense of exhaustion related to cancer or cancer treatment. To investigate potential risk factors for cancer-related fatigue in women with breast cancer undergoing whole breast radiotherapy (RT), we assessed the contribution of patient and disease characteristics, treatment with chemotherapy (CTX), RT-induced epidermal thickening, and inflammatory mediators to post RT fatigue. Following lumpectomy, 30 women received a definitive course of whole breast RT (50 Gy plus a 10 Gy boost). Prior to RT, at week 6 of RT, and 6 weeks post RT, subjects completed a validated questionnaire assessing fatigue (Multidimensional Fatigue Inventory [MFI-20]). On the MFI, a higher score means more fatigue. At the above visits, patients also underwent blood sampling for inflammatory mediators including plasma concentrations of c-reactive protein and interleukin (IL-6). In addition, breast epidermal thickness of the treated and untreated breast was measured using ultrasound tissue characterization. Fatigue scores in the sample as a whole did not increase during RT. Moreover, there was a significant decrease in fatigue scores by 6 weeks post RT (p = 0.02). Independent multivariate analyses of clinical and demographic factors revealed that prior CTX (p < 0.001) and age <50 (p = 0.03) were significant predictors of higher post-RT fatigue scores. Before, during, and after RT, CTX-treated patients had significantly higher mean fatigue scores than non-CTX-treated subjects. For example, mean MFI scores post RT in patients previously treated with CTX (n = 15) were 28 points higher than patients not treated with CTX (mean 61 vs. 33; p < 0.001), with a clinically meaningful difference being 10 points on the MFI. Race, cancer stage, and epidermal thickening (defined as a 50% increase over baseline during or after RT, n = 17) did not predict higher post-RT fatigue scores. Of the inflammatory mediators, plasma IL-6 prior to RT was the strongest predictor of post RT fatigue (p = .02). In addition, plasma IL-6 concentrations prior to RT were significantly higher in patients who received CTX vs. those who did not (mean 4.96 vs. 2.53, p = 0.01). IL-6 prior to RT was also significantly correlated with RT-induced epidermal thickening (p = 0.04). Our study suggests that CTX-induced inflammation, as measured by plasma IL-6, is independently associated with the development of fatigue as well as epidermal thickening in women undergoing breast RT. These data suggest that treatments targeting inflammation before RT may reduce both fatigue and epidermal thickening post RT, particularly in patients who have been previously been treated with CTX.